■本荟萃分析旨在评估pembrolizumab在晚期或复发性宫颈癌患者中的疗效和安全性。
■来自PubMed的数据库,Embase,和Cochrane图书馆都进行了彻底的搜索以进行相关研究。结果包括完全反应(CR),部分响应(PR),稳定的疾病(SD),疾病进展(PD),总反应率(ORR),疾病控制率(DCR),中位无进展生存期(mPFS),中位总生存期(mOS),和不良事件(AE)进行进一步分析。
■本荟萃分析包括10项721例患者的试验。接受pembrolizumab的宫颈癌患者的合并结果如下:CR(0.06,95CI:0.02-0.10),PR(0.15,95CI:0.08-0.22),SD(0.16,95CI:0.13-0.20),PD(0.50,95CI:0.25-0.75),ORR(0.26,95CI:0.11-0.41)和DCR(0.42,95CI:0.13-0.71),分别。关于生存分析,合并的mPFS和mOS分别为3.81个月和10.15个月.亚组分析显示,pembrolizumab组合在CR中更有益(0.16vs.0.03,p=0.012),PR(0.24vs.0.08,p=0.032),SD(0.11vs.0.19,p=0.043),ORR(0.42vs.0.11,p=0.014),和mPFS(5.54个月vs.2.27个月,p<0.001)比作为单一药剂。最常见的三种不良事件是腹泻(0.25),贫血(0.25),恶心(0.21),3-5级AE的发生率明显较低,很少超过0.10。
■对于晚期或复发性宫颈癌患者,本系统综述和荟萃分析显示,派姆单抗具有良好的疗效和耐受性.未来的研究将主要集中在优化定制的方案,最佳地将pembrolizumab整合到新疗法和组合策略中。旨在最大限度地提高患者的利益和有效地控制不良反应,同时保持高标准的生活。
这项研究证明了pembrolizumab在晚期或复发性宫颈癌患者中的疗效和安全性。研究发现,化疗和pembrolizumab免疫治疗的前期组合似乎是这些患者的一个引人注目的策略。未来将需要更多的大规模和多中心随机对照试验,以验证pembrolizumab在治疗宫颈癌的新疗法和联合策略中的确切益处。
UNASSIGNED: This meta-analysis seeks to assess the efficacy and safety of pembrolizumab in individuals with advanced or recurrent cervical cancer.
UNASSIGNED: Databases from PubMed, Embase, and the Cochrane Library were all thoroughly searched for pertinent research. Outcomes include complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), overall response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and adverse events (AEs) were retrieved for further analysis.
UNASSIGNED: Ten trials with 721 patients were included in this meta-analysis. The pooled results for patients with cervical cancer receiving pembrolizumab were as follows: CR (0.06, 95%CI: 0.02-0.10), PR (0.15, 95%CI: 0.08-0.22), SD (0.16, 95%CI: 0.13-0.20), PD (0.50, 95%CI: 0.25-0.75), ORR (0.26, 95%CI: 0.11-0.41) and DCR (0.42, 95%CI: 0.13-0.71), respectively. Regarding survival analysis, the pooled mPFS and mOS were 3.81 and 10.15 months. Subgroup analysis showed that pembrolizumab in combination was more beneficial in CR (0.16 vs. 0.03, p = 0.012), PR (0.24 vs. 0.08, p = 0.032), SD (0.11 vs. 0.19, p = 0.043), ORR (0.42 vs. 0.11, p = 0.014), and mPFS (5.54 months vs. 2.27 months, p < 0.001) than as single agent. The three most common AEs were diarrhoea (0.25), anaemia (0.25), and nausea (0.21), and the incidence of grade 3-5 AEs was significantly lower, rarely surpassing 0.10.
UNASSIGNED: For patients with advanced or recurrent cervical cancer, this systematic review and meta-analysis demonstrated that pembrolizumab had a favourable efficacy and tolerability. Future research will primarily focus on optimising customised regiments that optimally integrate pembrolizumab into new therapies and combination strategies. Designed to maximise patient benefit and efficiently control adverse effects while maintaining a high standard of living.
This study demonstrated the efficacy and safety of pembrolizumab in individuals with advanced or recurrent cervical cancer. The study found that an upfront combination of chemotherapy and pembrolizumab immunotherapy appears to be a compelling strategy for these patients. More large-scale and multicentre randomised controlled trials will be required in the future to validate the precise benefits of pembrolizumab in new therapies and combination strategies for the treatment of cervical cancer.